New approaches to understanding hallucinations in Parkinson's disease: Phenomenology and possible origins

Expert Review of Neurotherapeutics

Volumn 7, Issue 12, 2007, Pages 1731-1750

  Onofrj, Marco ^a   Thomas, Astrid ^a   Bonanni, Laura ^a  

^a UNIVERSITY OF CHIETI   (Italy)

Author keywords

Antipsychotic drugs; Charles Bonnet syndrome; Dementia with Lewy bodies; Parkinson's disease; Peduncular hallucinosis; Psychosis; REM sleep behavior disorder; Visual hallucinations

Indexed keywords

ALPHA SYNUCLEIN; ARIPIPRAZOLE; CHOLINESTERASE INHIBITOR; CLOMIPRAMINE; CLONAZEPAM; CLOZAPINE; NEUROLEPTIC AGENT; OLANZAPINE; PLACEBO; QUETIAPINE; RISPERIDONE; SEROTONIN ANTAGONIST; THIORIDAZINE; ZIPRASIDONE;

BRAIN DYSFUNCTION; CHARLES BONNET SYNDROME; CHOLINERGIC ACTIVITY; CLINICAL TRIAL; COGNITIVE DEFECT; DEMENTIA; DISEASE CLASSIFICATION; DREAM; FRONTAL LOBE; HALLUCINOSIS; HUMAN; LEWY BODY; LIMBIC SYSTEM; PARKINSON DISEASE; PEDUNCULAR HALLUCINOSIS; PHENOMENOLOGY; PROGNOSIS; PSYCHOSIS; REVIEW; SLEEP DISORDER; VISUAL DISORDER; VISUAL HALLUCINATION; VISUAL SYSTEM;

ANTIPSYCHOTIC AGENTS; HALLUCINATIONS; HUMANS; PARKINSON DISEASE;

EID: 37149033686     PISSN: 14737175     EISSN: 17448360     Source Type: Journal    
DOI: 10.1586/14737175.7.12.1731     Document Type: Review

References (223)

1. Arnulf I, Bonnet AM, Damier P et al. Hallucinations, REM sleep, and Parkinson's disease. Neurology 55, 281-288 (2000). • The original medical hypothesis that links visual hallucinations (VH) with dream overflow. The VH that coincide with daytime episodes of rapid eye movement (REM) sleep in patients who also experience post-REM delusions at night may be dream imagery. Psychosis in patients with Parkinson's disease (PD) may therefore reflect a narcolepsy-like REM sleep disorder.
2. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70, 734-738 (2001).
3. Pappert EJ, Goetz CG, Niederman FG, Raman R, Leurgans S. Hallucinations, sleep fragmentation, and altered dream phenomena in Parkinson's disease. Mov. Disord. 14(1), 117-121 (1999).
4. Tanner CM, Vogel C, Goetz CG, Klawans HL. Hallucinations in Parkinson's disease: a populational study. Ann. Neurol. 14, 136 (1983) (Abstract).
5. Goetz CG, Leurgans S, Pappert EJ, Raman R, Stemer AB. Prospective longitudinal assessment of hallucinations in Parkinson's disease. Neurology 57, 2078-2082 (2001).
6. Sanchez-Ramos JR, Ortoll R, Paulson GW. Visual hallucinations associated with Parkinson's disease. Arch. Neurol. 53, 1265-1268 (1996).
7. Onofrj M, Thomas A, D'Andreamatteo G et al. Incidence of RBD and hallucination in patients affected by Parkinson's disease: 8-year follow-up. Neurol. Sci. 23(Suppl. 2), S91-S94 (2002).
8. Holroyd S, Currie L, Wooten GF. Prospective study of hallucinations and delusions in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 70, 734-738 (2001).
9. Doe de Maindreville A, Fenelon G, Mahieux F. Hallucinations in Parkinson's disease: a follow-up study. Mov. Disord. 20(2), 212-217 (2005).
10. Goetz CG, Stebbins GT. Risk factors for nursing home placement in advanced Parkinson's disease. Neurology 43, 2227-2229 (1993).
11. Goetz CG, Stebbins GT. Mortality and hallucinations in nursing home patients with advanced Parkinson's disease. Neurology 45(4), 669-671(1995). •• The most quoted paper on mortality risk and VH. The study demonstrates the permanency of nursing home placement in advanced PD and the high mortality associated with such placement. It also documents the chronicity of hallucinatory behavior in these patients with advanced PD and reinforces our previously reported observations on the relationship between hallucinations and placement in chronic-care facilities.
12. Onofrj M, Bonanni L, Albani G, Mauro A, Bulla D, Thomas A. Visual hallucinations in Parkinson's disease: clues to separate origins. J. Neurol. Sci. 25, 143-150 (2006). • Review presenting new insights on VH. The studies support a recently proposed integrative model of visual hallucinations, and show that the neural circuits purported to explain hallucinations must include the retinal dopaminergic system and the REM sleep regulatory system.
13. Celesia GG, Barr AN. Psychosis and other psychiatric manifestations of levodopa therapy. Arch. Neurol. 23, 193-200 (1970).
14. Sharf B, Moskovitz C, Lupton MD, Klawans HL. Dream phenomena induced by chronic levodopa therapy. J. Neural. Transm. 43, 143-151 (1978).
15. Moskovitz C, Moses H, Klawans HL. Levodopa-induced psychosis: a kindling phenomenon. Am. J. Psychiatry 135(6), 669-675 (1978).
16. Goetz CG, Tanner CM, Klawans HL. Pharmacology of hallucinations induced by long term drug therapy. Am. J. Psychiatry 139, 494-497(1982).
17. Rondot P, De Recondo J, Coignet A, Zeigler M. Mental disorder in Parkinson's disease after treatment with L-dopa. Adv. Neurol. 40, 259-269 (1984).
18. Goetz CG, Vogel C, Tanner CM, Stebbins GT. Early dopaminergic drug induced hallucinations in parkinsonian patients. Neurology 51(3), 811-814 (1998).
19. Factor SA, Molho ES, Podskalny GD, Brown D. Parkinson's disease. Drug-induced psychiatric states. Adv. Neurol. 65, 115-138 (1995).
20. Okada K, Suyama N, Oguro H, Yamaguchi S, Kobayashi S. Medication-induced hallucination and cerebral blood flow in Parkinson's disease. J. Neurol. 246, 365-368 (1999).
21. Papapetropoulos S, Argyriou AA, Ellul J. Factors associated with drug-induced visual hallucinations in Parkinson's disease. J. Neurol. 252(10), 1223-1228 (2005).
22. Damasio AR, Lobo-Antunes J, Macedo C. Psychiatric aspects in parkinsonism treated with L-dopa. J. Neurol. Neurosurg. Psychiatry 34(5), 502-507 (1971).
23. Sacks OW, Kohl MS, Messeloff CR, Schwartz WF. Effects of levodopa in parkinsonian with dementia. Neurology 22(5), 516-519 (1972).
24. Chou KL, Messing S, Oakes D, Feldman PD, Breier A, Friedman JH. Drug-induced psychosis in Parkinson disease: phenomenology and correlations among psychosis rating instruments. Clin. Neuropharmacol. 28(5), 215-219 (2005).
25. Porteous HB, Ross DN. Mental symptoms in parkinsonism following benzhexol hydrochloride therapy. Br. Med. J. 2, 138-140 (1956).
26. Goetz CG, Pappert EJ, Blasucci LM et al. Intravenous levodopa in hallucinating Parkinson's disease patients: high-dose challenge does not precipitate hallucinations. Neurology 50, 515-517 (1998). • This study confutes the concept of dopaminergic psychosis. In the study, plasma levodopa levels changed significantly during the infusion protocol. All patients remained alert, and none developed VH. In conclusion, VH do not relate simply to high levels of levodopa or to sudden changes in plasma levels.
27. Merims D, Shabtai H, Korczyn AD, Peretz C, Weizman N, Giladi N. Antiparkinsonian medication is not a risk factor for the development of hallucinations in Parkinson's disease. J. Neural. Transm. 111, 1447-1453 (2004).
28. Fénelon G, Goetz CG, Karenberg A. Hallucinations in Parkinson disease in the prelevodopa era. Neurology 66(1), 93-98 (2006). •• Important clinical review. Whether chronic hallucinations belong to the natural history of untreated PD remains undetermined. Historical descriptions of PD from the pre-levodopa era suggest that hallucinations may be part of PD itself, especially in the context of late dementia, depression or nonspecific encephalopathy.
29. Consensus guidelines for the clinical and pathologic diagnosis of dementia with Lewy bodies (DLB): report of the Consortium on DLB International Workshop. J. Alzheimers Dis. 9(3 Suppl), 417-423 (2006).
30. Jellinger KA. Lewy body-related α-synucleinopathy in the aged human brain. J. Neural. Transm. 111(10-11), 1219-1235 (2004)
31. Boeve BF, Silber MH, Ferman TJ, Lucas JA, Parisi JE. Association of REM sleep behavior disorder and neurodegenerative disease may reflect an underlying synucleinopathy. Mov. Disord. 16(4), 622-630 (2001).
32. Aarsland D, Ballard C, Larsen JP, McKeith I. A comparative study of psychiatric symptoms in dementia with Lewy bodies and Parkinson's disease with and without dementia. Int. J. Geriat. Psychiatry 16, 528-536 (2001).
33. Boeve BF, Silber MH, Parisi JE et al. Synucleinopathy pathology and REM sleep behavior disorder plus dementia or parkinsonism. Neurology 61(1), 40-45 (2003).
34. Braak H, Del Tredici K, Rüb U et al. Staging of brain pathology related to sporadic Parkinson's disease. Neurobiol. Aging 24, 197-211 (2003).
35. Onofrj M. Disturbi Mentali nelle Sindromi Parkinsoniane. Springer-Verlag, Milano, Italia (2003).
36. Braak H, Rüb U, Steur ENH, Del Tredici K, de Vos RAI. Cognitive status correlates with neuropathologic stage in Parkinson disease. Neurology 64, 1404-1410 (2005).
37. Grossi D, Trojano L, Pellecchia MT, Amboni M, Fragassi NA, Barone P. Frontal dysfunction contributes to the genesis of hallucinations in nondemented parkinsonian patients. Int. J. Geriatr. Psychiatry 20, 668-673 (2005).
38. Williams D, Lees A. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 4, 605-610 (2005) •• The revolutionary study on VH and parkinsonism. The presence of VH is helpful in the differentiation of PD from other non-Lewy body causes of parkinsonism. They propose that VH be added, as a supportive criterion, to the operational clinical criteria for the diagnosis of PD.
39. Nomura T, Inoue Y, Mitani H, Kawahara Williams D, Lees A. Visual hallucinations in the diagnosis of idiopathic Parkinson's disease: a retrospective autopsy study. Lancet Neurol. 4, 605-610(2005).
40. Hughes AJ, Daniel SE, Kilford L, Lees AJ. Accuracy of clinical diagnosis of idiopathic Parkinson's disease: a clinico-pathological study of 100 cases. J. Neurol. Neurosurg. Psychiatry 55, 181-184 (1992).
41. Goetz CG, Burke PF, Leurgans S et al. Genetic variation analysis in parkinson disease patients with and without hallucinations: case-control study. Arch. Neurol. 58(2), 209-213 (2001)
42. Runge E. Psychosen bei Gehirnerkrankungen. In: Handbuch der Geisteskrankheiten. Bumke O (Ed.). Berlin Springer, Berlin, Germany 7, 526-680 (1928).
43. Gamper E. Paralysis agitans. In: Handbuch der Neurologie. Bumke O, Foerster O (Eds). Berlin, Springer, Germany 16, 757-827 (1936).
44. Ball B. De l 'insanité dans la paralysie agitante. Encéphale 2, 22-32 (1882).
45. Fenelon G, Mahieux F, Huon R, Ziegler M. Hallucinations in Parkinson's disease: prevalence, phenomenology and risk factors. Brain 123(Pt 4), 733-745 (2000). •• This study determined the phenomenology, prevalence and risk factors of hallucinations in PD. It was demonstrated that three factors were independently predictive of formed VH: severe cognitive disorders, daytime somnolence and a long duration of PD. The main risk factor in treated patients is cognitive impairment, although sleep-wake cycle disturbances and possibly other factors related to the duration of the disease act as cofactors.
46. Barnes J, David AS. Visual hallucinations in Parkinson's disease: a review and phenomenological survey. J. Neurol. Neurosurg. Psychiatry 70, 727-733 (2001).
47. Galvin JE, Pollack J, Morris JC. Clinical phenotype of Parkinson disease dementia. Neurology 67(9), 1605-1611 (2006).
48. Parant V. La paralysie agitante examinée comme cause de folie. Ann. Med. Psychol. (Paris) 10, 45-63 (1883).
49. Régis E. Précis de psychicatrie (4th Edition). Doin, Paris, France (1909).
50. König H. Zur Psychopatologie der Paralysie Agitante. Arch. Psychiat. Nervenkr. 50, 285-305 (1913).
51. Lewy FH. Die Lehre vom Tonus und der Bewegung. Zugleich systematische Untersuchunges zur Klinik, Physiologie, Pathologie und Pathogenese der Paralysis agitans. Springer, Berlin, Germany (1923).
52. Giladi N, Treves TA, Paleacu D et al. Risk factors for dementia, depression and psychosis in long-standing Parkinson's disease. J. Neural. Transm. 107(1), 59-71(2000).
53. Melamed E. Neurobehavioral abnormalities in Parkinson's disease. In: Movement Disorders. Watts RL, Koller C (Eds). McGraw Hill, NY, USA 257-262 (1996).
54. Ozer F, Meral H, Hanoglu L et al. Cognitive impairment patterns in Parkinson's disease with visual hallucinations. J. Clin. Neurosci. 14(8), 742-746 (2007).
55. Ffytche DH, Howard RJ. The perceptual consequences of visual loss: 'positive' pathologies of vision. Brain 122(Pt 7), 1247-1260 (1999).
56. Schultz G, Melzack R. Visual hallucinations and mental state. A study of 14 Charles Bonnet syndrome hallucinators. J. Nerv. Ment. Dis. 181(10), 639-643 (1993).
57. Teunisse RJ, Cruysberg JR, Verbeek A, Zitman FG. The Charles Bonnet syndrome: a large prospective study in The Netherlands. A study of the prevalence of the Charles Bonnet syndrome and associated factors in 500 patients attending the University Department of Ophthalmology at Nijmegen. Br. J. Psychiatry 166(2), 254-257 (1995).
58. Burke W. The neural basis of Charles Bonnet hallucinations: a hypothesis. J. Neurol. Neurosurg. Psychiatry 73, 535-541 (2002).
59. Schultz G, Needham W, Taylor R, Shindell S, Melzack R. Properties of complex hallucinations associated with deficits in vision. Perception 25(6), 715-726 (1996).
60. White NJ. Complex visual hallucinations in partial blindness due to eye disorders. Br. J. Psychiatry 36, 284-286 (1980).
61. Teunisse RJ, Zitman FG, Raes DC. Clinical evaluation of 14 patients with the Charles Bonnet syndrome (isolated visual hallucinations). Compr. Psychiatry 35, 70-75 (1994).
62. Cole M. When the left brain is not right the right brain may be left: report of personal experience of occipital hemianopia. J. Neurol. Neurosurg. Psychiatry 67, 169-173 (1999).
63. Ffytche DH. Visual hallucinatory syndromes: past, present, and future. Dialogues Clin. Neurosci. 9, 173-189 (2007) •• This article reviewed the history of visual hallucinatory syndromes and the eye dispute, together with advances in perceptual neuroscience that question core assumptions of our current approach. From a neurobiological perspective, three syndromes emerge that relate to specific dysfunctions of afferent, cholinergic and serotonergic visual circuitry and promise future therapeutic advances.
64. McKee AC, Levine DN, Kowall NW, Richardson EP Jr. Peduncular hallucinosis associated with isolated infarction of the substantia nigra pars reticulata. Ann. Neurol. 27, 500-504 (1990).
65. Liedholm LJ, Anjegard IM, de Flon P, Smedby T. Two cases of peduncular hallucinosis. Vivid, colorful and dancing images and figures. Lakartidningen 96(14), 1712-1715 (1999).
66. Benke T. Peduncular hallucinosis: a syndrome of impaired reality monitoring. J. Neurol. 253, 1561-1571 (2006).
67. Manford M, Andermann F. Complex visual hallucinations. Clinical and neurobiological insights. Brain 121(Pt 10), 1819-1840 (1998).
68. Santhouse AM, Howard RJ, Ffytche DH. Visual hallucinatory syndromes and the anatomy of the visual brain. Brain 123(Pt 10), 2055-2064 (2000).
69. Ffytche DH, Howard RJ, Brammer MJ, David A, Woodruff P, Williams S. The anatomy of conscious vision: in fMRI study of visual hallucinations. Nat. Neurosci. 1, 738-742 (1998).
70. Goetz CG, Fan W, Leurgans S, Bernard B, Stebbins GT. The malignant course of "benign hallucinations" in Parkinson disease. Arch. Neurol. 63, 713-716 (2006).
71. Inzelberg R, Kipervasser S, Korczyn AD. Auditory hallucinations in Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 64, 533-535 (1998).
72. Diederich NJ, Goetz CG, Stebbins GT. Repeated visual hallucinations in Parkinson's disease as disturbed external/internal perceptions: focused review and a new integrative model. Mov. Disord. 20, 130-140 (2005). • The most quoted model of VH origin. The authors suggest that visual hallucinations should be considered as a dysregulation of the gating and filtering of external perception and internal image production. This new conceptual framework permits an anatomical view of visual hallucinations and suggests new, testable hypotheses regarding their pathophysiology and therapy.
73. Onofrj M, Thomas A, Bonanni L, Iacono D, Gambi F. Leucopenia induced by low dose clozapine in Parkinson's disease recedes shortly after drug withdrawal (Review series). Psychiatry 2, 22-24 (2002).
74. Graham JM, Grnewald RA, Sagar HJ. Hallucinosis in idiopathic Parkinson's disease. J. Neurol. Neurosurg. Psychiatry 63, 434-440 (1997).
75. Poewe W. Psychosis in Parkinson's disease. Mov. Disord. 18(Suppl. 6), S80-S87 (2003).
76. Nebe A, Ebersbach G. Selective diplopia in Parkinson's disease: a special subtype of visual hallucination? Mov. Disord. 8, 1175-1178 (2007).
77. Repka MX, Claro MC, Loupe DN, Reich SG. Ocular motility in Parkinson's disease. J. Pediatr. Ophthalmol. Strabismus 33(3), 144-147 (1996).
78. Racette BA, Gokden MS, Tychsen LS, Perlmutter JS. Convergence insufficiency in idiopathic Parkinson's disease responsive to levodopa. Strabismus 7(3), 169-174 (1999).
79. Goetz CG, Li JM, Wuu J, Leurgans S. Does seasonal variation affect hallucinations in PD? A longitudinal study. Mov. Disord. 6, 863-865 (2006).
80. Chan D, Rossor MN "-but who is that on the other side of you?" Extracampine hallucinations revisited. Lancet 360, 2064-2066 (2002).
81. Critchley EM, Rossall CJ. Hallucinations. Br. J. Hosp. Med. 3, 264-270 (1978).
82. Husain AM, Miller PP, Carwile ST. REM sleep behavior disorder: potential relationship to post-traumatic stress disorder. J. Clin. Neurophysiol. 2, 148-157 (2001).
83. Diederich NJ, Pieri V, Goetz CG. Coping strategies for visual hallucinations in Parkinson's disease. Mov. Disord. 7, 831-832 (2003).
84. Kanazawa A, Hata T. Coexistence of the Ekbom syndrome and lilliputian hallucination. Psychopathology 4, 209-211 (1992).
85. Mosimann UP, Rowan EN, Partington CE et al. Characteristics of visual hallucinations in Parkinson's disease dementia and dementia with Lewy bodies. Am. J. Geriat. Psychiatry 2, 153-160 (2006).
86. Mahowald MW, Schenk CH. Status dissociatus - a perspective on state of being. Sleep 14, 69-79 (1991).
87. Lugaresi E, Provini F. Agrypnia excitata: clinical features and pathophysiological implications. Sleep Med. Rev. 4, 313-322 (2001).
88. Fantini ML, Corona A, Clerici S, Ferini-Strambi L. Aggressive dream content without daytime aggressiveness in REM sleep behaviour disorder. Neurology 65, 1010-1015 (2005).
89. Schenck CH, Bundlie SR, Mahowald MW. Delayed emergence of a parkinsonian disorder in 38% of 29 older men initially diagnosed with idiopathic rapid eye movement sleep behaviour disorder. Neurology 46, 388-393 (1996).
90. Fantini ML, Gagnon JF, Petit D et al. Slowing of electroencephalogram in rapid eye movement sleep behavior disorder. Ann. Neurol. 53, 774-780 (2003).
91. Massicotte-Marquez J, Carrier J, Décary A et al. Slow-wave sleep and delta power in rapid eye movement sleep behavior disorder. Ann. Neurol. 57, 277-282 (2005).
92. Celesia GG. The mystery of photopsias, visual hallucinations, and distortions. Suppl. Clin. Neurophysiol. 59, 97-103 (2006).
93. Panayiotopoulos CP. Elementary visual hallucinations, blindness, and headache in idiopathic occipital epilepsy: differentiation from migraine. J. Neurol. Neurosurg. Psychiatry 66, 536-540 (1999).
94. 3 receptor antagonist. Neurology 45, 1305-1308 (1995).
95. Eichhorn TE, Brunt E, Oertel WH. Ondansetron treatment of L-dopa-induced psychosis. Neurology 47, 1608-1609 (1996).
96. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson's disease: preliminary experience. Clin. Neuropharmacol. 1, 4-5 (2004).
97. Wolters EC, Jansen EN, Tuynman-Qua HG, Bergmens PL. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 47, 1085-1087 (1996).
98. Jiménez-Jiménez FJ, Tallón-Barranco A, Ortí-Pareja M, Zurdo M, Porta J, Molina JA. Olanzapine can worsen Parkinsonism. Neurology 50, 1183-1184 (1998).
99. Friedman JH, Goldstein SM. Olanzapine in the treatment of dopaminomimetic psychosis in patients with Parkinson's disease. Neurology 50, 1195-1196 (1998).
100. Factor SA, Molho ES, Friedman JH. Risperidone and Parkinson's disease. Mov. Disord. 17, 221-225 (2001).
101. Molho ES, Factor SA. Parkinson's disease: the treatment of drug-induced hallucinations and psychosis. Curr. Neurol. Neurosci. Rep. 14, 320-328 (2001).
102. Ellis T, Cudkowicz ME, Sexton PM, Growdon JH. Clozapine and risperidone treatment of psychosis in Parkinson's disease. J. Neuropsychiatr. Clin. Neurosci. 12, 364-369 (2000).
103. Fernandez HH, Donnelly EM, Friedman JH. Long-term outcome of clozapine use for psychosis among parkinsonian patients. Mov. Disord. 19, 831-833 (2004).
104. Greene P, Cote L, Fahn S. Treatment of drug-induced psychosis in Parkinson's disease with clozapine. In: Advances in Neurology, Parkinson's Disease: From Basic Research to Treatment. Narabayashi N, Nagatsu T, Yanagisawa N, Mizuno Y (Eds). Raven, NY, USA 702-706 (1993).
105. Aarsland D, Larsen JP, Lim NG, Tandberg E. Olanzapine for psychosis in patients with Parkinson's disease with and without dementia. J. Neuropsychiatr. Clin. Neurosci. 11, 392-394 (1999).
106. Goetz CG, Blasucci LM, Leurgans S, Pappert EJ. Olanzapine and clozapine: comparative effects on motor function in hallucinating PD patients. Neurology 55, 789-794 (2000).
107. Friedman JH, Fernandez HH. Atypical antipsychotics in Parkinson sensitive populations. J. Geriatr. Psychiatr. Neurol. 15, 156-170 (2002).
108. Reddy S, Factor S, Molho E, Feustel P. The effect of quetiapine on psychosis and motor function in patients with and without dementia. Mov. Disord. 17, 676-681 (2002).
109. Fernandez HH, Trieschmann ME, Burke MA, Jacques C, Friedman JH. Long-term outcome of quetiapine use for psychosis among Parkinsonian patients. Mov. Disord. 18, 510-514 (2003).
110. Ondo WG, Vuong KD, Ringholz G. Quetiapine for drug-induced psychosis in Parkinson's disease: a double-blind, placebo-controlled, parallel trial. Mov. Disord. 18, 1083 (2003).
111. Wolters EC, Hurwitz TA, Mak E et al. Clozapine in the treatment of parkinsonian patients with dopaminomimetic psychosis. Neurology 40, 832-834 (1990).
112. Parkinson Study Group. Low dose clozapine for the treatment of drug-induced psychosis in Parkinson's disease. N. Engl. J. Med. 340, 757-763 (1999).
113. French Clozapine Parkinson Study Group. Clozapine in drug induced psychosis in Parkinson's disease. Lancet 353, 2041-2042 (1999).
114. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 151, 201-211 (2000).
115. Factor SA, Friedman JH. The emerging role of clozapine in the treatment of movement disorders. Mov. Disord. 12, 483-496 (1997).
116. Friedman JH, Berman RM, Goetz CG et al. Open-label flexible-dose pilot study to evaluate the safety and tolerability of aripiprazole in patients with psychosis associated with Parkinson's disease. Mov. Disord. 21, 2078-2081 (2006).
117. Singh Ajit S. Does aripiprazole have a role in treating cognitive impairment in Parkinson's disease? J. Neuropsychiatr. Clin. Neurosci. 19, 205-206 (2007).
118. Wickremaratchi M, Morris HR, Ali IM. Aripiprazole associated with severe exacerbation of Parkinson's disease. Mov. Disord. 21, 1538-1539 (2006).
119. Lopez-Meza E, Ruiz-Chow A, Ramirez-Bermudez J. Aripiprazole in psychosis associated with Parkinson's disease. J. Neuropsychiatr. Clin. Neurosci. 17, 421-422 (2005).
120. Fernandez HH, Trieschmann ME, Friedman JH. Aripiprazole for drug-induced psychosis in Parkinson disease: preliminary experience. Clin. Neuropharmacol. 27, 4-5 (2004).
121. Barbato L, Monge A, Stocchi F, Nordera G. Melperone in the treatment of iatrogenic psychosis in Parkinson's disease. Funct. Neurol. 11, 201-207 (1996).
122. Wint DP, Okun MS, Fernandez HH. Psychosis in Parkinson's disease. J. Geriatr. Psychiatry Neurol. 17, 127-136 (2004).
123. Diederich NJ, Alesch F, Goetz CG. Visual hallucinations induced by deep brain stimulation in Parkinson's disease. Clin. Neuropharmacol. 23, 287-289 (2000).
124. Dujardin K, Krystkowiak P, Defebvre L, Blond S, Destée A. A case of severe dysexecutive syndrome consecutive to chronic bilateral pallidal stimulation. Neuropsychologia 38, 1305-1315 (2000).
125. Bejjani BP, Damier P, Arnulf I et al. Transient acute depression induced by high-frequency deep-brain stimulation. N. Engl. J. Med. 13, 1476-1480 (1999).
126. Krack P, Kumar R, Ardouin C et al. Mirthful laughter induced by subthalamic nucleus stimulation. Mov. Disord. 16, 867-875 (2001).
127. Kuczenski R, Segal DS. Psychomotor stimulant-induced sensitization: behavior and neurochemical correlates. In: Sensitization in the Nervous System. Kalivas PW, Barnes CD (Eds). Telford Press, NJ, USA 177-205 (1988).
128. Romito LM, Raja M, Daniele A et al. Transient mania with hypersexuality after surgery for high frequency stimulation of the subthalamic nucleus in Parkinson's disease. Mov. Disord. 17, 1371-1374 (2002).
129. Harding AJ, Broe GA, Halliday GM. Visual hallucinations in Lewy body disease relate to Lewy bodies in the temporal lobe. Brain 125, 391-403 (2002).
130. Ffytche DH. Visual hallucinations and the Charles Bonnet syndrome. Curr. Psychiatr. Rep. 7, 168-179 (2005).
131. Perry EK, Marshall E, Thompson P et al. Monoaminergic activities in Lewy body dementia: relation to hallucinosis and extrapyramidal features. J. Neural Transm. 6, 167-177 (1993).
132. Perry EK, Perry RH. Acetylcholine and hallucinations: disease related compared to drug-induced alterations in human consciousness. Brain Cogn. 28, 240-258 (1995).
133. Teaktong T, Piggott MA, Mckeith IG, Perry RH, Ballard CG, Perry EK. Muscarinic M2 and M4 receptors in anterior cingulate cortex: relation to neuropsychiatric symptoms in dementia with Lewy bodies. Behav. Brain Res. 161, 299-305 (2005).
134. Perry EK, Marshall E, Kerwin J et al. Evidence of a monoaminergic-cholinergic imbalance related to visual hallucinations in Lewy body dementia. J. Neurochem. 55, 1454-1456 (1990).
135. Perry E, Walker M, Grace J, Perry R. Acetylcholine in mind: a neurotransmitter correlate of consciousness? Trends Neurosci. 22, 273-280 (1999).
136. Poewe W, Wolters E, Emre M et al. Long-term benefits of rivastigmine in dementia associated with Parkinson's disease: an active treatment extension study. Mov. Disord. 21, 456-461 (2006).
137. Reading PJ, Luce AK, McKeith IG. Rivastigmine in the treatment of parkinsonian psychosis and cognitive impairment: preliminary findings from an open trial. Mov. Disord. 16, 1171-1195 (2001).
138. McKeith IG, Wesnes KA, Perry E, Ferrara R. Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy bodies. Dement. Geriatr. Cogn Disord. 18, 94-100 (2004).
139. Perry EK, Kilford L, Lees AJ, Burn DJ, Perry RH. Increased Alzheimer pathology in Parkinson's disease related to antimuscarinic drugs. Ann. Neurol. 54, 235-238 (2003).
140. Chaudhuri KR, Healy DG, Schapira AH. Non-motor symptoms of Parkinson's disease: diagnosis and management. Lancet Neurol. 5, 235-245 (2006).
141. Bodis-Wollner I, Onofrj M. Visual system in Parkinson's disease. In: Advances in Neurology. Yahr MD, Bergmann KJ (Eds). 45, 323-327 (1986).
142. Ghilardi MF, Bodis-Wollner I, Onofrj M, Marx MS, Glover AA. Spatial frequency-dependent abnormalities of the pattern electroretinogram and visual evoked potentials in a parkinsonian monkey model. Brain 3, 131-149 (1988).
143. Bodis-Wollner I, Yahr MD. Measurements of visual evoked potentials in Parkinson's disease. Brain 101, 667-671 (1979).
144. Factor SA, McAlarney T, Sanchez-Ramos JR, Weiner WJ. Sleep disorders and sleep effect in Parkinson's disease. Mov. Disord. 5, 280-285 (1990).
145. Comella CL, Tanner CM, Ristanovic RK. Polysomnographic sleep measures in Parkinson's disease patients with treatment induced hallucinations. Ann. Neurol. 34, 710-714 (1993).
146. Pacchetti C, Manni R, Zangaglia R et al. Relationship between hallucinations, delusions, and rapid eye movement sleep behavior disorder in Parkinson's disease. Mov. Disord. 20, 1439-1448 (2005).
147. Hobson JA, Pace-Schott EF, Stickgold R. Dreaming and the brain: toward a cognitive neuroscience of conscious states. Behav. Brain Sci. 23, 793-842; discussion 904-1121 (2000).
148. Takata K, Inoue Y, Hazama H, Fukuma E. Night-time hypnopompic visual hallucinations related to REM sleep disorder. Psychiatry Clin. Neurosci. 52, 207-209 (1998).
149. Manni R, Pacchetti C, Terzaghi M, Sartori I, Mancini F, Nappi G. Hallucinations and sleep-wake cycle in PD. Neurology 59, 1979-1981 (2002).
150. Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Mov. Disord. 18, 812-817 (2003).
151. Onofrj M, Luciano AL, Iacono D et al. HLA typing does not predict REM sleep behaviour disorder and hallucinations in Parkinson's disease. Mov. Disord. 18, 337-340 (2003).
152. Schenck CH, Bundlie SR, Ettinger MG, Mahowald MW. Chronic behavioural disorders of human REM sleep: a new category of parasomnia. Sleep 9, 293-308 (1986).
153. Thomas A, Bonanni L, Onofrj M. Symptomatic REM sleep behaviour disorder. Neurol Sci. 28(Suppl. 1), S21-S36 (2007).
154. Onofrj M, Curatola L, Ferracci F, Fulgente T. Narcolepsy associated with primary temporal lobe β-cells lymphoma in a HLA DR2 negative subject. J. Neurol. Neurosurg. Psychiatry 55, 852-853 (1992).
155. Thannickal TC, Lai YY, Siegel JM. Hypocretin (orexin) cell loss in Parkinson's disease. Brain 130, 1586-1595 (2007).
156. Oka H, Yoshioka M, Onouchi K et al. Impaired cardiovascular autonomic function in Parkinson's disease with visual hallucinations. Mov. Disord. 22, 1510-1514 (2007)
157. Kitayama M, Wada-Isoe K, Irizawa Y, Nakashima K. Association of visual hallucinations with reduction of MIBG cardiac uptake in Parkinson's disease. J. Neurol. Sci. (2007) (Epub ahead of print).
158. Owen AM. Cognitive dysfunction in Parkinson's disease: the role of frontostriatal circuitry. Neuroscientist 6, 525-537 (2004).
159. Goldberg E. The Executive Brain. Oxford University Press, NY, USA 1-251 (2001).
160. Goldberg E. Gradiental approach to neocortical functional organization. J. Clin. Exp. Neuropsychol. 4, 489-517 (1989).
161. Goldberg E. The frontal lobes in neurological and psychiatric conditions. Neuropsychiatry Neuropsychol. Behav. Neurol. 5, 231-232 (1992).
162. Treisman A. Features and objects: the fourteenth Bartlett memorial lecture. Q. J. Exp. Psychol. A 40, 201-237 (1988).
163. Stebbins GT, Goetz CG, Carrillo MC et al. Altered cortical visual processing in PD with hallucinations: an fMRI study. Neurology 63, 1409-1416 (2004).
164. Ramírez-Ruiz B, Martí MJ, Tolosa E et al. Longitudinal evaluation of cerebral morphological changes in Parkinson's disease with and without dementia. J. Neurol. 11, 1345-1352 (2005)
165. Francis PT, Perry EK. Cholinergic and other neurotransmitter mechanisms in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies. Mov. Disord. (2007) (Epub ahead of print).
166. Borek LL, Kohn R, Friedman JH. Phenomenology of dreams in Parkinson's disease. Mov. Disord. 22(2), 198-202 (2007).
167. Mathis J, Hess CW, Bassetti C. Isolated mediotegmental lesion causing narcolepsy and rapid eye movement sleep behaviour disorder: a case evidencing a common pathway in narcolepsy and rapid eye movement sleep behaviour disorder. J. Neurol. Neurosurg. Psychiatry 78, 427-429 (2007)
168. Gagnon JF, Postuma RB, Montplaisir J. Update on the pharmacology of REM sleep behavior disorder. Neurology 67, 742-747 (2006).
169. Onofrj M, Thomas A. Severe worsening of parkinsonism in Lewy body dementia due to donepezil. Neurology 61, 1452 (2003).
170. Bullock R, Cameron A. Rivastigmine for the treatment of dementia and visual hallucinations associated with Parkinson's disease: a case series. Curr. Med. Res. Opin. 18, 258-264 (2002).
171. Kolmel HW. Peduncular hallucinations. J. Neurol. 8, 457-459 (1991).
172. Aarsland D, Litvan I, Larsen JP. Neuropsychiatric symptoms of patients with progressive supranuclear palsy and Parkinson's disease. J. Neuropsychiatr. Clin. Neurosci. 13, 42-49 (2001).
173. Papapetropoulos S, Mash DC. Visual hallucinations in progressive supranuclear palsy. Eur. Neurol. 54, 217-219 (2005).
174. Nagano-Saito A, Washimi Y, Arahata Y et al. Visual hallucination in Parkinson's disease with FDG PET. Mov. Disord. 7, 801-806 (2004).
175. Oishi N, Udaka F, Kameyama M, Sawamoto N, Hashikawa K, Fukuyama H. Regional cerebral blood flow in Parkinson disease with nonpsychotic visual hallucinations. Neurology 65, 1708-1715 (2005).
176. Holroyd S, Wooten GF. Preliminary fMRI evidence of visual system dysfunction in Parkinson's disease patients with visual hallucinations. J. Neuropsychiatr. Clin. Neurosci. 3, 402-404 (2006).
177. Molho ES, Factor SA. Parkinson's disease: the treatment of drug induced hallucinations and psychosis. Curr. Neurol. Neurosci. Rep. 1, 320-328 (2001).
178. Juncos JL. Management of psychotic aspects of Parkinson's disease. J. Clin. Psychiatry 60(Suppl. 8), 42-53 (1999).
179. Friedman JH, Factor SA. Atypical antipsychotics in the treatment of drug-induced psychosis in Parkinson's disease. Mov. Disord. 2, 201-211 (2000).
180. Movement Disorders Society. Management of Parkinson's disease: an evidence-based review drugs to treat dementia and psychosis. Mov. Disord. 17(Suppl. 4), S120-S127 (2002).
181. Poewe W. Psychosis in Parkinson's disease. Mov. Disord. 18(Suppl. 6), S80-S87 (2003).
182. Frieling H, Hillemacher T, Ziegenbein M, Neundorfer B, Bleich S. Treating dopamimetic psychosis in Parkinson's disease: structured review and meta-analysis. Eur. Neuropsychopharmacol. 3, 165-171 (2007).
183. Seppi K, Sampaio C, Sawires M, Costa J, Poewe W. Treatment of psychosis in Parkinson's disease. (Protocol) The Cochrane Collaboration. Cochrane Database of Systematic Reviews 4 (2007).
184. Factor SA, Brown D, Molho ES, Podskalny GD. Clozapine: a 2-year open trial in Parkinson's disease patients with psychosis. Neurology 44, 544-546 (1994).
185. Morgante L, Epifanio A, Spina E et al. Quetiapine and clozapine in parkinsonian patients with dopaminergic psychosis. Clin. Neuropharmacol. 27, 153-156 (2004).
186. Merims D, Balas M, Peretz C, Shabtai H, Giladi N. Rater-blinded, prospective comparison: quetiapine versus clozapine for Parkinson's disease psychosis. Clin. Neuropharmacol. 29, 331-337 (2006).
187. Ondo WG, Levy JK, Vuong KD, Hunter C, Jankovic J. Olanzapine treatment for dopaminergic-induced hallucinations. Mov. Disord. 17, 1031-1035 (2002).
188. Breier A, Sutton VK, Feldman PD et al. Olanzapine in the treatment of dopamimetic -induced psychosis in patients with Parkinson's disease. Biol. Psychiatry 52, 438-445 (2002).
189. Leopold NA. Risperidone treatment of drug-related psychosis in patients with parkinsonism. Mov. Disord. 15, 301-304 (2000).
190. Mohr E, Mendis T, Hildebrand K, De Deyn PP. Risperidone in the treatment of dopamine-induced psychosis in Parkinson's disease: an open pilot trial. Mov. Disord. 6, 1230-1237 (2000).
191. Rabey JM, Prokhorov T, Miniovitz A, Dobronevsky E, Klein C. Effect of quetiapine in psychotic Parkinson's disease patients: a double-blind labeled study of 3 months' duration. Mov. Disord. 22, 313-318 (2007).
192. Prohorov T, Klein C, Miniovitz A, Dobronevsky E, Rabey JM. The effect of quetiapine in psychotic parkinsonian patients with and without dementia an open-labeled study utilizing a structured interview. J. Neurol. 253, 171-175 (2006).
193. Klein C, Prokhorov T, Miniovich A, Dobronevsky E, Rabey JM. Long-term follow-up (24 months) of quetiapine treatment in drug-induced Parkinson disease psychosis. Clin. Neuropharmacol. 29, 215-219 (2006).
194. Juncos JL, Roberts VJ, Evatt ML et al. Quetiapine improves psychotic symptoms and cognition in Parkinson's disease. Mov. Disord. 1, 29-35 (2004).
195. Rudolf J, Grond M, Neveling M, Heiss W. Clozapine-induced agranulocytosis and thrombocytopenia in a patient with dopaminergic psychosis. J. Neural. Transm. 104, 1305-1311 (1997).
196. Ravina B, Marder K, Fernandez HH et al. Diagnostic criteria for psychosis in Parkinson's disease: report of an NINDS, NIMH work group. Mov. Disord. 8, 1061-1068 (2007). •• The authors reviewed the existing literature on PD-psychosis (PDPsy) to provide criteria that distinguish PDPsy from other causes of psychosis. They proposed provisional criteria for PDPsy in the style of the Diagnostic and Statistical Manual of Mental Disorders IV-TR. PDPsy has a well-characterized temporal and clinical profile of hallucinations and delusions. PDPsy is associated with Lewy body pathology, imbalances of monoaminergic neurotransmitters and visuospatial processing deficits. These findings suggest that PDPsy may result from progression of the disease process underlying PD.
197. Fernandez HH, Trieschmann ME, Okun MS. "Rebound psychosis": effect of discontinuation of antipsychotics in Parkinson's disease. Mov. Disord. 20, 104-105 (2005).
198. Onofrj M, Thomas A. Acute akinesia in Parkinson disease. Neurology 64, 1162-1169 (2005).
199. Thomas A, Iacono D, Luciano AL, Armellino K, Onofrj M. Acute akinesia or akinetic crisis in Parkinson's disease. Neurol. Sci. 3, 219-220 (2003).
200. Nausieda PA, Glantz R, Weber S, Baum R, Klawans HL. Psychiatric complications of levodopa therapy of Parkinson's disease. Adv. Neurol. 40, 271-277 (1984).
201. Wilde MI, Markham A. Ondansetron. A review of its pharmacology and preliminary clinical findings in novel applications. Drugs 5, 773-794 (1996).
202. Meco G, Bernardi S. Antidepressant use in treatment of psychosis with comorbid depression in Parkinson's disease. Prog. Neuropsychopharmacol. Biol. Psychiatry 31, 311-313 (2007).
203. Schindehütte J, Trenkwalder C. Treatment of drug-induced psychosis in Parkinson's disease with ziprasidone can induce severe dose-dependent off-periods and pathological laughing. Clin. Neurol. Neurosurg. 109, 188-191 (2007).
204. Nomura T, Inoue Y, Mitani H, Kawahara R, Miyake M, Nakashima K. Visual hallucinations as REM sleep behavior disorders in patients with Parkinson's disease. Mov. Disord. 18, 812-817 (2003).
205. Kurita A, Ochiai Y, Kono Y, Suzuki M, Inoue K. The beneficial effect of donepezil on visual hallucinations in three patients with Parkinson's disease. J. Geriatr. Psychiatry Neurol. 16, 184-188 (2003)
206. Aarsland D, Laake K, Larsen JP, Janvin C. Donepezil for cognitive impairment in Parkinson's disease: a randomised controlled study. J. Neurol. Neurosurg. Psychiatry 72, 708-712 (2002).
207. Fabbrini G, Barbanti P, Aurilia C, Pauletti C, Lenzi GL, Meco G. Donepezil in the treatment of hallucinations and delusions in Parkinson's disease. Neurol. Sci. 23, 41-43 (2002).
208. Aarsland D, Hutchinson M, Larsen JP. Cognitive, psychiatric and motor response to galantamine in Parkinson's disease with dementia. Int. J. Geriatr. Psychiatry 18, 937-941 (2003).
209. Sobow T. Parkinson's disease-related visual hallucinations unresponsive to atypical antipsychotics treated with cholinesterase inhibitors: a case series. Neurol. Neurochir. Pol. 41, 276-279 (2007).
210. Gugger JJ, Wagner ML. Rapid eye movement sleep behavior disorder. Ann. Pharmacother. 41, 1833-1841 (2007)
211. Bodis-Wollner I. Neuropsychological and perceptual defects in Parkinson's disease. Parkinsonism Relat. Disord. 9, S83-S89 (2003)
212. Arnulf I., Bonnet Harnois C, Di Paolo T. Decreased dopamine in the retinas of patients with Parkinson's disease. Invest. Ophthalmol. Vis. Sci. 31, 2473-2475 (1990)
213. Bodis-Wollner I. Visual deficits related to dopamine deficiency in experimental animals and Parkinson's disease patients. Trends Neurosci. 13, 296-302 (1990).
214. Diederich NJ, Goetz CG, Raman R, Pappert EJ, Leurgans S, Piery V. Poor visual discrimination and visual hallucinations in Parkinson's disease. Clin. Neuropharmacol. 21, 289-295 (1998).
215. Pieri V, Diedrich NJ, Raman R, Goetz CG. Decreased color discrimination and contrast sensitivity in Parkinson's disease. J. Neurol. Sci. 172, 7-11 (2000).
216. Maurage CA, Ruchoux MM, de Vos R, Surguchov A, Destee A. Retinal involvement in dementia with Lewy bodies: a clue to hallucinations. Ann. Neurol. 54, 542-247 (2003).
217. Onofrj M, Bodis-Wollner I. Dopaminergic deficiency causes delayed visual evoked potentials in rats. Ann. Neurol. 11, 484-490 (1982).
218. Onofrj M, Ghilardi MF, Basciani M, Gambi D. Visual evoked potentials in Parkinsonism and dopamine blockade reveal a stimulus-dependent dopamine function in humans. J. Neurol. Neurosurg. Psychiatry 49, 1150-1159 (1986).
219. Ghilardi MF, Chung E, Bodis-Wollner I, Dvorzniak M, Glover A, Onofrj M. Systemic 1-methyl, 4-phenyl, 1-2-3-6 tetrahydropyridine (MPTP) administration decreases retinal dopamine content in primates. Life Sci. 43, 255-262 (1988).
220. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology 44, 2308-2314 (1994).
221. 1A receptor agonism. Brain Res. 956, 349-357 (2002).
222. Stocchi F, Arnold G, Onofrj M et al. Safinamide Parkinson's Study Group. Improvement of motor function in early Parkinson disease by safinamide. Neurology 63, 746-748 (2004).
223. Onofrj M, Luciano AL, Thomas A, Iacono D, D'Andreamatteo G. Mirtazapine induces REM sleep behavior disorder (RBD) in parkinsonism. Neurology 60, 113-115 (2003).